Logo

Henlius Reports First Patient Dosing in P-I Study of HLX04-O (biosimilar- bevacizumab) for Wet Age-Related Macular Degeneration

Share this
Henlius Reports First Patient Dosing in P-I Study of HLX04-O (biosimilar- bevacizumab) for Wet Age-Related Macular Degeneration

Henlius Reports First Patient Dosing in P-I Study of HLX04-O (biosimilar- bevacizumab) for Wet Age-Related Macular Degeneration

Shots:

  • The first patient has been dosed in a P-I study of HLX04-O conducting in patients with wAMD. The primary objective of the study is to evaluate the safety & tolerability of HLX04-O in 6-12 patients with wAMD
  • The secondary objective of the study is to evaluate the PK profiles of HLX04-O after intravitreal injection
  • In Oct’2020- Henlius signed co-development and exclusive license agreement with Essex. The companies plan to conduct clinical trials of HLX04-O in China- Australia- EU- and the US- and apply marketing authorization in different countries and regions across the globe

Click here to read full press release/ article | Ref: Henlius | Image: nature


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions